Double-expressor Lymphoma (DEL)
2 clinical trials · Condition
◉ Watch Double-expressor Lymphoma (DEL)
| Record | Firm | Date |
|---|---|---|
| Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma (NCT01742988) | Curis, Inc. | 2012-12-01 |
Track Double-expressor Lymphoma (DEL) automatically
Every clearance here is in the API, with alerts when new ones post.